Do Patents Prevent Access to Drugs for HIV in Developing Countries?

Differential pricing of antiretroviral medications between industrialized and developing drug markets should be systematically and promptly adopted not after several years of delay. Generic competition should be encouraged and exceptions to patent rights should be widely supported in the case of highly active antiretroviral therapy in developing countries. (excerpt)